康缘药业 (600557.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

9.2x

Market Cap

CNY 6.74B

MomentumView details →

1D Return

−1.24%

YTD Return

−11.27%

RSI (14)

49.3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

9.2x

Market Cap

CNY 6.74B

RSI (14)

49.3

MomentumView details →

1D Return

−1.24%

YTD Return

−11.27%

ProfitabilityView details →

Gross Margin

71.61%

Net Margin

9.23%

EBITDA Margin

17.53%

ROE (TTM)

6.12%

ROA (TTM)

4.35%

Asset Turnover

0.47x

GrowthView details →

Revenue YoY

−4.99%

EPS YoY

−10.98%

FCF YoY

—

Revenue CAGR 3Y

−8.87%

EPS CAGR 3Y

−10.37%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.14

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

−1.21%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

1.93x

Quick Ratio

1.66x

Div Yield

—

Div Rate

—

Div Growth 1Y

+69.10%

Financials snapshotView financials →

Revenue (TTM)

3.25B

Net Income (TTM)

299.79M

Op. CF (TTM)

599.55M

Latest newsMore news →

Kangyuan Pharmaceutical reported its first-half 2026 results: net profit attributable to shareholders of 147 million yuan, up 3.36% year-on-year.9d ago

Similar companies

China Traditional Chinese Medicine Holdings Co. Limited00570.HK 百克生物688276.SH 中牧股份600195.SH Lantheus Holdings, Inc.LNTH 亚虹医药-U688176.SH 中恒集团600252.SH Find similar companies →

Latest newsMore news →

Kangyuan Pharmaceutical reported its first-half 2026 results: net profit attributable to shareholders of 147 million yuan, up 3.36% year-on-year.9d ago